Johnson & Johnson will break ground on its new, 500,000 square foot, state-of-the-art biologics manufacturing facility in Wilson, North Carolina, which will expand its capacity to deliver transformational medicines for people living with cancer, immune-mediated and neurological diseases. The groundbreaking will be marked by an event that features perspectives from key Company leaders and national, state and local officials on the impact of this investment for patients and the community at large. This event represents a significant milestone as part of the Company’s announcement that it is increasing its U.S. research and development, technology and manufacturing investments to more than $55 billion over the next four years.
“We are pleased to make this significant investment in our manufacturing network in the United States. This state-of-the-art biologics facility in North Carolina will help Johnson & Johnson to accelerate the delivery of our portfolio and pipeline of transformational medicines for patients,” said Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson & Johnson. “This $2 billion investment will bring more than 5,000 high-wage manufacturing and construction jobs to North Carolina and the partnerships we are forging in the community will support local educational initiatives to develop the workforce of the future.”
“Wilson is an important life sciences hub, and I am excited to welcome Johnson & Johnson as it expands its manufacturing footprint in our state,” said Governor Josh Stein. “I look forward to seeing the impact this investment will have on medical innovation and North Carolina’s workforce.”
Comments powered by CComment